4-(3-Alkyl-2-oxoimidazolidin-1-yl)-N-phenylbenzenesulfonamides as new antimitotic prodrugs activated by cytochrome P450 1A1 in breast cancer cells
Authors:
- 1 October 2018
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 26 (18) , 5045-5052
Abstract
No abstract availableKeywords
Funding Information
- Canada Foundation for Innovation
This publication has 26 references indexed in Scilit:
- Drug Resistance and the Role of Combination Chemotherapy in Improving Patient OutcomesInternational Journal of Breast Cancer, 2013
- Estrogen-Dependent Gene Transcription in Human Breast Cancer Cells Relies upon Proteasome-Dependent Monoubiquitination of Histone H2BCancer Research, 2011
- Design, Synthesis, Biological Evaluation, and Structure–Activity Relationships of Substituted Phenyl 4-(2-Oxoimidazolidin-1-yl)benzenesulfonates as New Tubulin Inhibitors Mimicking Combretastatin A-4Journal of Medicinal Chemistry, 2011
- The Role of Aryl Hydrocarbon Receptor and Crosstalk with Estrogen Receptor in Response of Breast Cancer Cells to the Novel Antitumor Agents Benzothiazoles and AminoflavoneInternational Journal of Breast Cancer, 2011
- Profiling the expression of cytochrome P450 in breast cancerHistopathology, 2010
- GeneSigDB—a curated database of gene expression signaturesNucleic Acids Research, 2009
- Organization of Cytochrome P450 Enzymes Involved in Sex Steroid SynthesisJournal of Biological Chemistry, 2009
- Cytochrome P450 and Chemical ToxicologyChemical Research in Toxicology, 2007
- CYP1A Induction and Human Risk Assessment: An Evolving Tale of in Vitro and in Vivo StudiesDrug Metabolism and Disposition, 2007
- Cytochromes P450 as versatile biocatalystsJournal of Biotechnology, 2006